Abstract | INTRODUCTION: There is an urgent need for novel agents to manage serious bacterial infections, particularly those contracted in healthcare facilities. Tigecycline is a novel broad-spectrum glycylcycline with good activity against Gram-positive, many Gram-negative, anaerobic, and some atypical pathogens that has been developed to address this need. AIMS: EVIDENCE REVIEW: OUTCOMES SUMMARY: The introduction of tigecycline should be beneficial at a time of increasing problems with bacterial resistance, and evidence to date has been sufficient for regulatory approval for complicated SSSIs and intraabdominal infections. Research into tigecycline's efficacy in other infectious diseases (notably pneumonia and bacteremia) is ongoing. Further good quality studies and ongoing surveillance for any emerging bacterial resistance will be needed to determine outcomes with tigecycline relative to other novel antibacterial agents, and to explore the economic implications of its adoption.
|
Authors | Christopher J Dunn |
Journal | Core evidence
(Core Evid)
Vol. 1
Issue 3
Pg. 181-94
( 2006)
ISSN: 1555-1741 [Print] New Zealand |
PMID | 22500153
(Publication Type: Journal Article)
|